New Biotech Company Will Focus on POC Diagnostics
By HospiMedica staff writers
Posted on 17 Oct 2007
A new biotech company will develop methods for personalized medicine based on new technologies and advanced data analysis. Posted on 17 Oct 2007
One of the focus areas of the company will be to develop techniques for point-of-care (POC) diagnostics of different diseases. The techniques developed will also be used for monitoring the patient's condition during and after treatment.
"We have promising results for arthritis, where several different studies show consistent results regarding biomarkers that can distinguish healthy subjects from diagnosed patients. The study is based on serum samples and the goal is to establish collaborations and have a POC diagnostic kit for arthritis on the market in a few years,” commented Jon Gabrielsson, CEO of the new company, AcureOmics AB (Umea, Sweden).
Robust and consistent techniques for analysis of metabolites/biomarkers will also be developed. Development work is ongoing for monitoring the physiologic effects of food supplements. The company also aims to use chemometrics to become competent in the "omics” (genomics, proteomics, and metabolomics/metabonomics) field of data analysis and interpretation.
Related Links:
AcureOmics
Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control
